Comparison · NCT04394715-315c5271
Intervention vs Control: Proportion of Patients With Intensification of Lipid Lowering Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention vs Control: Proportion of Patients With Intensification of Lipid Lowering Therapy. Trial comparisons, record NCT04394715-315c5271. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04394715-315c5271
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.141 | 0.122 | 0.162 | wilson | |
| Risk in group 2 | 0.104 | 0.0886 | 0.121 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0371 | 0.0113 | 0.0633 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 1.1 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.42 | 1.11 | 1.8 | log | |
| Number needed to treat, for one more participant with the outcome on Intervention than on Control | 27 | 15.8 | 88.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention | Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.~Electronic Alert: Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits. | 159 | 1,130 | OG000 |
| Group 2 | Control | Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members. | 142 | 1,370 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Proportion of Patients With Intensification of Lipid Lowering Therapy
- Description
Intensification of lipid lowering therapy is defined as an increase in statin dose, an addition of ezetimibe, or addition of PCSK9. Any one of the three will be sufficient to meet this endpoint. Proportion of patients who meet this endpoint will be compared between study arms.
- Time frame
- 90 days from first alert for any given patient
- Population
Source ClinicalTrials.gov
Trial
- Title
- Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)
- NCT number
- NCT04394715
- Phases
- NA
- Conditions
- High Risk Atherosclerotic Cardiovascular Disease
- Interventions
- Electronic Alert
- Lead sponsor
- Yale University
- Results first posted
- 2024-09-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04394715?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04394715-315c5271